Work

Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249

Year: 2016
Type: letter
Abstract: We would like to congratulate Kazda et al. (1) for reporting the first phase 2 study of the glucagon receptor antagonist LY2409021 as a novel therapy for type 2 diabetes. This study provides further proof of efficacy of glucagon antagonism as a treatment for type 2 diabetes with acceptable adverse effects at a dose of 30 mg. However, we would like the authors to clarify certain points in the phase 2a study, which would help readers …
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2532504933
Cites: 3
Cited by: 27
Related to: 10